Evidence map›Paper›PMID 39960841›Full record

Trial reportClinical and translational science2025

Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects.

Jie Cheng, Hongjie Qian, Yu Wang, Liyu Liang, Wenjing Xu, Ye Liu, Qian Chen, Chen Yu, Huaqing Duan, Zhen Wang and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jie ChengDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0009-0007-8566-3506
Hongjie QianDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-5209-805X
Yu WangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0009-0005-7004-349X
Liyu LiangDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2478-9152
Wenjing XuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0009-0002-0433-4596
Ye LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0009-0007-7315-3429
Qian ChenDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-9834-6912
Chen YuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-6814-0638
Huaqing DuanVigonvita Life Sciences Co., Ltd., Suzhou, China.ORCID 0009-0001-6626-1508
Zhen WangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-9450-2260
Hang WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-0849-1196
Jingying JiaDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2492-3219

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the effects of the concomitant administration of TPN171 and alcohol on hemodynamic and pharmacokinetic characteristics in healthy Chinese male subjects. Fifteen eligible subjects were randomly assigned to one of three sequences, each comprising three treatments: Treatment A (placebo +0.5 g/kg alcohol), Treatment B (TPN171 + 0.5 g/kg alcohol), and Treatment C (TPN171 + placebo). Enrolled subjects were administered with 10 mg TPN171 and/or 0.5 g/kg alcohol in fasting state in a randomized crossover design. Blood pressure, pulse rate (PR), blood samples, and breath alcohol test were measured at designated time points for hemodynamic and pharmacokinetic analyses. Compared with 10 mg TPN171 alone, administration of 10 mg TPN171 + 0.5 g/kg alcohol significantly lowered the area under the effect-time curve from 0 to 4 h (AUEC

Indexed as

EthanolHemodynamicsAdultBlood PressureBreath TestsCross-Over StudiesDrug InteractionsHealthy VolunteersHeart RateHumansMaleYoung AdultEthanolalcoholhealthy subjectshemodynamicsPDE5 inhibitorpharmacokineticsTPN171

Identifiers

PMID39960841
PMCPMC11832027

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.